Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Von E confirmation reheats

This article was originally published in The Tan Sheet

Executive Summary

Senate Finance chair Chuck Grassley (R-Iowa) places a hold on the nomination of Andrew von Eschenbach's nomination for FDA Commissioner Nov. 17. Grassley objects to the acting commissioner's failure to comply with subpoenas the committee issued in May for FDA documents related to Sanofi-Aventis' antibiotic Ketek. "The authority and integrity of Senate and Committee processes are being challenged," says Grassley. A day earlier, during a hearing on drug safety, Senate Health Committee Chairman Michael Enzi (R-Wyo.) urged colleagues to take up a vote on the nominee. "Give Dr. von Eschenbach the chance to effectively run the FDA with full statutory authority," Enzi said. Holds from Sen. David Vitter (R-La.) and Sen. Jim DeMint (R-S.C.) also remain in place. After the hearing, Enzi told reporters he continues working to lift those holds. If action is not taken during the lame duck session, incoming chair Edward Kennedy (D-Mass.), who supports the nomination, appears likely to continue to press for confirmation...

You may also be interested in...



Congressional Oversight “Misunderstood” By Von Eschenbach – Grassley

Continued criticism of FDA Acting Commissioner Andrew von Eschenbach by Senate Finance Committee Chairman Charles Grassley (R-Iowa) suggests that chances of a Senate vote on the nominee as full commissioner during Congress' lame-duck session have not brightened

Pipeline Watch: Four Approvals And 21 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris: Customer Dialogue Has Changed From Price, Price, Price To Availability

Viatris has weighed in on the FTC’s continued investigations into US healthcare middlemen, arguing that it can be a good thing for an industry battling shortages, even as the firm continues to rationalize products that do not make sense economically.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099974

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel